Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Regulation Approvals

Keeping Track: Nucala, Genvoya Approved; New Breakthrough Claims For Daiichi Sankyo, Merck Oncologics

  • Analysis

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib

Oncology news and highlights from our US FDA Performance Tracker.

Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved

The latest drug development news and highlights from our FDA Performance Tracker.

Keeping Track: Pfizer’s Zavzpret Brings Nasal Delivery To CGRP Antagonists; Ionis/AZ Advance Antisense Eplontersen In ATTR

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Regulation Approvals
Latest Headlines

Australia To Seek Stakeholder Input On Terms Of HTA Review

A Milestone Moment For Pharmacogenomics: US FDA Ready To Drop ‘Voluntary’ Program

Electronic Records: US FDA Updates Guidelines On Use In Clinical Investigations

Device Component Of Intarcia’s Diabetes Treatment ITCA 650 Worries FDA

See All
UsernamePublicRestriction

Register

PS057250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By